Caricamento...
Evaluation of Pegylated Liposomal Doxorubicin Dose on the Adverse Drug Event Profile and Outcomes in Treatment of Recurrent Endometrial Cancer
OBJECTIVE: To determine factors which may increase the likelihood of adverse drug events (ADEs) in recurrent endometrial cancer patients treated with pegylated liposomal doxorubicin (PLD) as well as this agent’s impact on clinical outcomes. METHODS: The treatment records of endometrial cancer patien...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3899886/ https://ncbi.nlm.nih.gov/pubmed/23295941 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IGC.0b013e31827c18f3 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|